Genmab A/S (GMAB)
51.00
-0.35
(-0.68%)
USD |
NASDAQ |
Nov 20, 10:47
Genmab Free Cash Flow : 843.28M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | 843.28M |
| June 30, 2026 | 869.04M |
| March 31, 2026 | 875.28M |
| December 31, 2025 | 1.134B |
| September 30, 2025 | 1.215B |
| June 30, 2025 | 969.96M |
| March 31, 2025 | 1.130B |
| December 31, 2024 | 1.089B |
| September 30, 2024 | 940.80M |
| June 30, 2024 | 936.43M |
| March 31, 2024 | 774.45M |
| December 31, 2023 | 1.010B |
| September 30, 2023 | 818.96M |
| June 30, 2023 | 797.76M |
| March 31, 2023 | 874.93M |
| December 31, 2022 | 503.50M |
| September 30, 2022 | 497.40M |
| June 30, 2022 | 313.25M |
| March 31, 2022 | 206.92M |
| December 31, 2021 | 314.39M |
| September 30, 2021 | 184.94M |
| June 30, 2021 | 865.02M |
| March 31, 2021 | 813.91M |
| December 31, 2020 | 941.18M |
| September 30, 2020 | 1.066B |
| Date | Value |
|---|---|
| June 30, 2020 | 348.39M |
| March 31, 2020 | 401.83M |
| December 31, 2019 | 181.05M |
| September 30, 2019 | 190.76M |
| June 30, 2019 | 178.02M |
| March 31, 2019 | 170.90M |
| December 31, 2018 | 148.86M |
| September 30, 2018 | 157.55M |
| June 30, 2018 | 136.10M |
| March 31, 2018 | 192.80M |
| December 31, 2017 | 228.19M |
| September 30, 2017 | 175.34M |
| June 30, 2017 | 196.89M |
| March 31, 2017 | 153.08M |
| December 31, 2016 | 43.97M |
| September 30, 2016 | 94.63M |
| June 30, 2016 | 84.52M |
| March 31, 2016 | 35.79M |
| December 31, 2015 | 26.33M |
| September 30, 2015 | -8.005M |
| June 30, 2015 | -23.50M |
| March 31, 2015 | 2.984M |
| December 31, 2014 | 10.25M |
| September 30, 2014 | 5.989M |
| June 30, 2014 | -7.968M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| AbbVie, Inc. | 18.87B |
| Incyte Corp. | 679.87M |
| Ascendis Pharma A/S | 598.04M |
| Zealand Pharma A/S | -249.09M |
| Bavarian Nordic A/S | 107.22M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 520.21M |
| Cash from Investing (Quarterly) | -9.000M |
| Cash from Financing (Quarterly) | -150.93M |
| Free Cash Flow Per Share (Quarterly) | 0.816 |
| Free Cash Flow to Equity (Quarterly) | 584.22M |
| Free Cash Flow to Firm (Quarterly) | 616.34M |
| Free Cash Flow Yield | 2.69% |